The only anti-IL-5 to demonstrate powerful and lasting reduction in exacerbations and OCS dose for up to 4.8 years in patients with severe eosinophilic asthma.123Now available with the power to choose: at home or in office administration. 5Transform the lives of your patients with the powerful and lasting protection of Nucala.1
ED, emergency department; ICS, inhaled corticosteroid; IL-5, interleukin-5; OCS, oral corticosteroid
Nucala is generally well tolerated. Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occured mainly wihin the first 3 injections.5
*Annualised rate at Week 24: 0.51/year vs. 1.21/year; p<0.0001 (additional study endpoint) 2
**Annualised rate at Week 24; 0.03/year vs. 0.10/year; p=0.031 (additional study endpoint) 2
†At Week 24 when added to high-dose ICS and additional maintenance treatment; Nucala n=69, placebo n=66 (secondary study endpoint). 3
††Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder.5
- GlaxoSmithKline Data on File REF-26441.
- Chupp GL et al. Lancet Respir Med 2017; 5:390-400.
- Bel EH et al. N Engl J Med 2014; 371: 1189-1197.
- Khatri S et al. J Allergy Clin Immunol 2019; 143:1742-1751.e7 (including supplementary materials).
- Nucala SmPC
- de Carvalho-Pinto RM, et al. Respir Med. 2012;106:47–56.
- Albers FC, et al. J Asthma. 2018;55:152–160.